According to an article published online in Neurology (r) the American Academy of Neurology’s medical journal, a drug approved recently to treat migraines may begin working immediately. This study examined the drug, atogepant. It is a calcitonin-related peptide receptor antagonist that can be taken orally. Richard B. Lipton MD is a fellow of the American Academy of Neurology and the author of this study. He works at Albert Einstein College of Medicine, in Bronx. The study found that people who took the drug atogepa
nt had a lower risk of a headache on their first day compared with those who were taking a control. The study participants also experienced fewer headaches each week in the four first weeks and overall compared to those who took a placebo. Researchers looked at data collected from three studies on atogepant’s safety and efficacy over a period of 12 weeks in order to determine how quickly improvements occurred. In the ADVANCE study, which included people who suffer from episodic migraines, 222 patients took atogepant and 214 placebos. ELEVATE, a trial that enrolled episodic migraine patients who previously had not responded to oral prevention treatments well, had 151 people on the drug, and 154 taking placebo. In the PROGRESS study, where people with chronic headache were enrolled, 256 patients received the drug, and 246 placebos.
People who suffer from episodic migraine can experience as many as 14 migraines per month. Chronic migraine sufferers experience headaches at least fifteen days per month. At least eight of those days are migraine-like.
At the beginning of the ADVANCE study, 12 % of participants had migraines, while 25% of placebo-takers did. The numbers for the second study, the ELEVATE test, were 15 and 26. The numbers for the third trial (the PROGRESS study) were 51% and 60%. Researchers found that when they adjusted for factors which could influence migraine rates, people who took the drug had a 61% lower chance of getting a migraine during the first study, compared to 47% in the second, and 37% in the third. In the first two studies, people who took atogepant experienced an average one day less of migraines per week compared with those on placebo. In the third study, the average number of migraines per week decreased by 1.5 days between those who took the drug and those who were taking a placebo. The atogepant-taking people also improved their assessments on how migraine affected their quality of life and activities compared with the placebo group. Lipton stated. The study was limited by the fact that the participants were mostly white women. Results may therefore not be applicable to all populations. AbbVie is the manufacturer of atogepant.